{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:59:18Z","timestamp":1787003958765,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T00:00:00Z","timestamp":1485475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T00:00:00Z","timestamp":1485475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Inducing degradation of oncoproteins by small molecule compounds has the potential to avoid drug resistance and therefore deserves to be exploited for new therapies. Oridonin is a natural compound with promising antitumor efficacy that can trigger the degradation of oncoproteins; however, the direct cellular targets and underlying mechanisms remain unclear. Here we report that oridonin depletes BCR-ABL through chaperon-mediated proteasomal degradation in leukemia. Mechanistically, oridonin poses oxidative stress in cancer cells and directly binds to cysteines of HSF1, leading to the activation of this master regulator of the chaperone system. The resulting induction of HSP70 and ubiquitin proteins and the enhanced binding to CHIP E3 ligase hence target BCR-ABL for ubiquitin-proteasome degradation. Both wild-type and mutant forms of BCR-ABL can be efficiently degraded by oridonin, supporting its efficacy observed in cultured cells as well as mouse tumor xenograft assays with either imatinib-sensitive or -resistant cells. Collectively, our results identify a novel mechanism by which oridonin induces rapid degradation of BCR-ABL as well as a novel pharmaceutical activator of HSF1 that represents a promising treatment for leukemia.<\/jats:p>","DOI":"10.1038\/srep41525","type":"journal-article","created":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T06:59:41Z","timestamp":1485500381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia"],"prefix":"10.1038","volume":"7","author":[{"given":"Huilin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyou","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianghu","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,27]]},"reference":[{"key":"BFsrep41525_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrc2559","volume":"9","author":"J Zhang","year":"2009","unstructured":"Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9, 28\u201339 (2009).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep41525_CR2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.neo.2015.08.008","volume":"17","author":"D Ray","year":"2015","unstructured":"Ray, D., Cuneo, K. C., Rehemtulla, A., Lawrence, T. S. & Nyati, M. K. Inducing Oncoprotein Degradation to Improve Targeted Cancer Therapy. Neoplasia 17, 697\u2013703 (2015).","journal-title":"Neoplasia"},{"key":"BFsrep41525_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1158\/2159-8290.CD-11-0087","volume":"1","author":"J Ablain","year":"2011","unstructured":"Ablain, J., Nasr, R., Bazarbachi, A. & de The, H. The drug-induced degradation of oncoproteins: an unexpected Achilles\u2019 heel of cancer cells? Cancer Discov 1, 117\u2013127 (2011).","journal-title":"Cancer Discov"},{"key":"BFsrep41525_CR4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley, J. D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290\u2013293 (1973).","journal-title":"Nature"},{"key":"BFsrep41525_CR5","first-page":"100","volume":"56","author":"E Buchdunger","year":"1996","unstructured":"Buchdunger, E. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56, 100\u2013104 (1996).","journal-title":"Cancer Res"},{"key":"BFsrep41525_CR6","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876\u2013880 (2001).","journal-title":"Science"},{"key":"BFsrep41525_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","volume":"359","author":"N von Bubnoff","year":"2002","unstructured":"von Bubnoff, N., Schneller, F., Peschel, C. & Duyster, J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359, 487\u2013491 (2002).","journal-title":"Lancet"},{"key":"BFsrep41525_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117\u2013125 (2002).","journal-title":"Cancer Cell"},{"key":"BFsrep41525_CR9","doi-asserted-by":"publisher","first-page":"33260","DOI":"10.1074\/jbc.272.52.33260","volume":"272","author":"M Warmuth","year":"1997","unstructured":"Warmuth, M. et al. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem 272, 33260\u201333270 (1997).","journal-title":"J Biol Chem"},{"key":"BFsrep41525_CR10","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1182\/blood.V99.11.4122","volume":"99","author":"JA Wertheim","year":"2002","unstructured":"Wertheim, J. A. et al. BCR-ABL-induced adhesion defects are tyrosine kinase-independent. Blood 99, 4122\u20134130 (2002).","journal-title":"Blood"},{"key":"BFsrep41525_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin, A. S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 121, 396\u2013409 (2011).","journal-title":"J Clin Invest"},{"key":"BFsrep41525_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.5966\/sctm.2012-0159","volume":"3","author":"CV Ichim","year":"2014","unstructured":"Ichim, C. V. Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors. Stem Cells Transl Med 3, 405\u2013415 (2014).","journal-title":"Stem Cells Transl Med"},{"key":"BFsrep41525_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/cr.2007.21","volume":"17","author":"GB Zhou","year":"2007","unstructured":"Zhou, G. B., Chen, S. J., Wang, Z. Y. & Chen, Z. Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo . Cell Res 17, 274\u2013276 (2007).","journal-title":"Cell Res"},{"issue":"127","key":"BFsrep41525_CR14","doi-asserted-by":"publisher","first-page":"127ra38","DOI":"10.1126\/scitranslmed.3003562","volume":"4","author":"T. Zhen","year":"2012","unstructured":"Zhen, T. et al. Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. Sci Transl Med 4, 127ra138 (2012).","journal-title":"Science Translational Medicine"},{"key":"BFsrep41525_CR15","doi-asserted-by":"publisher","first-page":"6543","DOI":"10.2174\/1381612820666140826153203","volume":"20","author":"H Huang","year":"2014","unstructured":"Huang, H., Weng, H., Zhou, H. & Qu, L. Attacking c-Myc: targeted and combined therapies for cancer. Curr Pharm Des 20, 6543\u20136554 (2014).","journal-title":"Curr Pharm Des"},{"key":"BFsrep41525_CR16","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-12-0066","volume":"11","author":"HL Huang","year":"2012","unstructured":"Huang, H. L. et al. Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol Cancer Ther 11, 1155\u20131165 (2012).","journal-title":"Mol Cancer Ther"},{"key":"BFsrep41525_CR17","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1158\/0008-5472.CAN-13-1748","volume":"74","author":"H Weng","year":"2014","unstructured":"Weng, H. et al. Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. Cancer Res 74, 4409\u20134419 (2014).","journal-title":"Cancer Res"},{"key":"BFsrep41525_CR18","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1158\/1535-7163.MCT-06-0006","volume":"5","author":"V Rapozzi","year":"2006","unstructured":"Rapozzi, V., Cogoi, S. & Xodo, L. E. Antisense locked nucleic acids efficiently suppress BCR\/ABL and induce cell growth decline and apoptosis in leukemic cells. Mol Cancer Ther 5, 1683\u20131692 (2006).","journal-title":"Mol Cancer Ther"},{"key":"BFsrep41525_CR19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1006\/bbrc.1997.7527","volume":"239","author":"TW Schulte","year":"1997","unstructured":"Schulte, T. W., An, W. G. & Neckers, L. M. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Commun 239, 655\u2013659 (1997).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep41525_CR20","first-page":"355","volume":"11","author":"WG An","year":"2000","unstructured":"An, W. G., Schulte, T. W. & Neckers, L. M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 11, 355\u2013360 (2000).","journal-title":"Cell Growth Differ"},{"key":"BFsrep41525_CR21","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1182\/blood-2009-10-249623","volume":"116","author":"F Tsukahara","year":"2010","unstructured":"Tsukahara, F. & Maru, Y. Bag1 directly routes immature BCR-ABL for proteasomal degradation. Blood 116, 3582\u20133592 (2010).","journal-title":"Blood"},{"key":"BFsrep41525_CR22","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/onc.2012.144","volume":"32","author":"I Paul","year":"2013","unstructured":"Paul, I., Ahmed, S. F., Bhowmik, A., Deb, S. & Ghosh, M. K. The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity. Oncogene 32, 1284\u20131295 (2013).","journal-title":"Oncogene"},{"key":"BFsrep41525_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ccr.2008.08.002","volume":"14","author":"MV Powers","year":"2008","unstructured":"Powers, M. V., Clarke, P. A. & Workman, P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 14, 250\u2013262 (2008).","journal-title":"Cancer Cell"},{"key":"BFsrep41525_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1242\/jcs.132605","volume":"127","author":"A Vihervaara","year":"2014","unstructured":"Vihervaara, A. & Sistonen, L. HSF1 at a glance. J Cell Sci 127, 261\u2013266 (2014).","journal-title":"J Cell Sci"},{"key":"BFsrep41525_CR25","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1093\/emboj\/20.14.3800","volume":"20","author":"CI Holmberg","year":"2001","unstructured":"Holmberg, C. I. et al. Phosphorylation of serine 230 promotes inducible transcriptional activity of heat shock factor 1. EMBO J 20, 3800\u20133810 (2001).","journal-title":"EMBO J"},{"key":"BFsrep41525_CR26","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0006-291X(03)00398-X","volume":"303","author":"F Soncin","year":"2003","unstructured":"Soncin, F. et al. Transcriptional activity and DNA binding of heat shock factor-1 involve phosphorylation on threonine 142 by CK2. Biochem Biophys Res Commun 303, 700\u2013706 (2003).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep41525_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/(SICI)1097-4652(199705)171:2<143::AID-JCP4>3.0.CO;2-O","volume":"171","author":"AT McDuffee","year":"1997","unstructured":"McDuffee, A. T. et al. Proteins containing non-native disulfide bonds generated by oxidative stress can act as signals for the induction of the heat shock response. J Cell Physiol 171, 143\u2013151 (1997).","journal-title":"J Cell Physiol"},{"key":"BFsrep41525_CR28","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1074\/jbc.271.9.4805","volume":"271","author":"H Liu","year":"1996","unstructured":"Liu, H., Lightfoot, R. & Stevens, J. L. Activation of heat shock factor by alkylating agents is triggered by glutathione depletion and oxidation of protein thiols. J Biol Chem 271, 4805\u20134812 (1996).","journal-title":"J Biol Chem"},{"key":"BFsrep41525_CR29","doi-asserted-by":"crossref","first-page":"30718","DOI":"10.1016\/S0021-9258(18)43873-2","volume":"269","author":"LE Huang","year":"1994","unstructured":"Huang, L. E., Zhang, H., Bae, S. W. & Liu, A. Y. Thiol reducing reagents inhibit the heat shock response. Involvement of a redox mechanism in the heat shock signal transduction pathway. J Biol Chem 269, 30718\u201330725 (1994).","journal-title":"J Biol Chem"},{"key":"BFsrep41525_CR30","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1248\/cpb.24.2118","volume":"24","author":"E Fujita","year":"1976","unstructured":"Fujita, E., Nagao, Y., Kaneko, K., Nakazawa, S. & Kuroda, H. The antitumor and antibacterial activity of the Isodon diterpenoids. Chem Pharm Bull (Tokyo) 24, 2118\u20132127 (1976).","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"BFsrep41525_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nrc795","volume":"2","author":"WC Hahn","year":"2002","unstructured":"Hahn, W. C. & Weinberg, R. A. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2, 331\u2013341 (2002).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep41525_CR32","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","volume":"136","author":"J Luo","year":"2009","unstructured":"Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823\u2013837 (2009).","journal-title":"Cell"},{"key":"BFsrep41525_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/science.1073096","volume":"297","author":"IB Weinstein","year":"2002","unstructured":"Weinstein, I. B. Cancer. Addiction to oncogenes\u2013the Achilles heal of cancer. Science 297, 63\u201364 (2002).","journal-title":"Science"},{"key":"BFsrep41525_CR34","doi-asserted-by":"publisher","first-page":"120144","DOI":"10.1098\/rsob.120144","volume":"3","author":"J Watson","year":"2013","unstructured":"Watson, J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol 3, 120144 (2013).","journal-title":"Open Biol"},{"key":"BFsrep41525_CR35","doi-asserted-by":"publisher","first-page":"6007","DOI":"10.1021\/bi702185u","volume":"47","author":"M Lu","year":"2008","unstructured":"Lu, M. et al. Two distinct disulfide bonds formed in human heat shock transcription factor 1 act in opposition to regulate its DNA binding activity. Biochemistry 47, 6007\u20136015 (2008).","journal-title":"Biochemistry"},{"key":"BFsrep41525_CR36","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/biom4030704","volume":"4","author":"A Shiber","year":"2014","unstructured":"Shiber, A. & Ravid, T. Chaperoning proteins for destruction: diverse roles of Hsp70 chaperones and their co-chaperones in targeting misfolded proteins to the proteasome. Biomolecules 4, 704\u2013724 (2014).","journal-title":"Biomolecules"},{"key":"BFsrep41525_CR37","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1038\/onc.2014.349","volume":"34","author":"MY Sherman","year":"2015","unstructured":"Sherman, M. Y. & Gabai, V. L. Hsp70 in cancer: back to the future. Oncogene 34, 4153\u20134161 (2015).","journal-title":"Oncogene"},{"key":"BFsrep41525_CR38","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1182\/blood-2004-05-2041","volume":"105","author":"F Guo","year":"2005","unstructured":"Guo, F. et al. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 105, 1246\u20131255 (2005).","journal-title":"Blood"},{"key":"BFsrep41525_CR39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.canlet.2015.02.013","volume":"368","author":"G Multhoff","year":"2015","unstructured":"Multhoff, G., Pockley, A. G., Schmid, T. E. & Schilling, D. The role of heat shock protein 70 (Hsp70) in radiation-induced immunomodulation. Cancer Lett 368, 179\u2013184 (2015).","journal-title":"Cancer Lett"},{"key":"BFsrep41525_CR40","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.1128\/MCB.19.6.4535","volume":"19","author":"CA Ballinger","year":"1999","unstructured":"Ballinger, C. A. et al. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol 19, 4535\u20134545 (1999).","journal-title":"Mol Cell Biol"},{"key":"BFsrep41525_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/35050618","volume":"3","author":"P Connell","year":"2001","unstructured":"Connell, P. et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 3, 93\u201396 (2001).","journal-title":"Nat Cell Biol"},{"key":"BFsrep41525_CR42","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1074\/jbc.M109.068577","volume":"285","author":"W Luo","year":"2010","unstructured":"Luo, W. et al. Hsp70 and CHIP selectively mediate ubiquitination and degradation of hypoxia-inducible factor (HIF)-1alpha but Not HIF-2alpha. J Biol Chem 285, 3651\u20133663 (2010).","journal-title":"J Biol Chem"},{"key":"BFsrep41525_CR43","doi-asserted-by":"crossref","unstructured":"Acquaviva, J. et al. mTOR Inhibition Potentiates HSP90 Inhibitor Activity via Cessation of Heat Shock Protein Synthesis. Mol Cancer Res (2014).","DOI":"10.1158\/1541-7786.MCR-13-0605"},{"key":"BFsrep41525_CR44","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.4161\/rna.21210","volume":"9","author":"HY Weng","year":"2012","unstructured":"Weng, H. Y., Huang, H. L., Zhao, P. P., Zhou, H. & Qu, L. H. Translational repression of cyclin D3 by a stable G-quadruplex in its 5\u2032 UTR: implications for cell cycle regulation. RNA Biol 9, 1099\u20131109 (2012).","journal-title":"RNA Biol"},{"key":"BFsrep41525_CR45","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1101\/gad.1044503","volume":"17","author":"SG Ahn","year":"2003","unstructured":"Ahn, S. G. & Thiele, D. J. Redox regulation of mammalian heat shock factor 1 is essential for Hsp gene activation and protection from stress. Genes Dev 17, 516\u2013528 (2003).","journal-title":"Genes Dev"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep41525.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep41525","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep41525.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T19:29:03Z","timestamp":1671823743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep41525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,27]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,2,13]]}},"alternative-id":["BFsrep41525"],"URL":"https:\/\/doi.org\/10.1038\/srep41525","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,27]]},"assertion":[{"value":"7 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41525"}}